These charts tell a heck of a story about Equity Risk Sciences and the market in general. Our system at Equity Risk Sciences dates back to the 80s. We rate over 15,000 companies on every trading day for over 35 years.
Net Present Value (NPV) is one of the most important tools for evaluating whether a stock is overvalued, undervalued, or fairly priced. It helps investors determine whether they are buying a stock with a high probability of profit—or one that is overpriced and likely to decline.
On 12/12/2024, MANH closed at $309.78. On that date, ERS’s V1™ rating was 100, the PRI™ was 99, and the FRR™ was 94. ERS’s eValuation™ rating was -142. Manhattan Associates closed today at $222.84. It fell 28.1% on the past 48 days.
Today, JetBlue (JBLU)’s stock price fell -25%. We’re using JetBlue as an example of the accuracy and value of ERS’s proprietary risk and performance ratings to RIAs, fiduciaries and institutional investors.
This report aims to provide an in-depth analysis of NVIDIA's (NVDA) current market valuation, comparing its financial outlook with historical data and market trends. The purpose is to educate optimistic investors about the fundamental principles of investing, grounded in rationality, historical context, and financial data.
When we received updated financial statements for Agilysys on 11/15/2024, all of ERS’s risk ratings immediately and significantly changed to reflect the much higher level of risk.
Fiduciaries must answer seven key questions about a company’s financial condition before investing. A fiduciary’s duty is to protect client interests, avoiding speculative decisions that could jeopardize financial security.
The 7 largest U.S. asset managers, collectively managing $38 trillion in assets, are incorporating AI into their investment advisory services. Goldman Sachs today announced it is “[rolling] out an AI assistant for its employees as artificial intelligence sweeps Wall Street”.
Investing without a scientific understanding of risk exposes portfolios to unnecessary losses. According to ERS's Fiduciary Risk Rating, FNMA has always been unsuitable for fiduciaries to own.
On 8/30/2024, Eli Lilly’s (LLY) market cap was $864 billion, price $960, and $39 billion TTM revenues. Its P/S was 22. Advisors using ERS’s ProfitMap.ai could have quickly and easily seen “what must happen” for LLY’s price to rise.